The fatal trajectory of pulmonary COVID-19 is driven by lobular ischemia and fibrotic remodelling.

ABSTRACT:

Background

COVID-19 is characterized by a heterogeneous clinical presentation, ranging from mild symptoms to severe courses of disease. 9-20% of hospitalized patients with severe lung disease die from COVID-19 and a substantial number of survivors develop long-COVID. Our objective was to provide comprehensive insights into the pathophysiology of severe COVID-19 and to identify liquid biomarkers for disease severity and therapy response.

Methods

We studied a total of 85 lungs (n = 31 COVID autopsy samples; n = 7 influenza A autopsy samples; n = 18 interstitial lung disease explants; n = 24 healthy controls) using the highest resolution Synchrotron radiation-based hierarchical phase-contrast tomography, scanning electron microscopy of microvascular corrosion casts, immunohisto

SUBMITTER: Ackermann M 

PROVIDER: S-EPMC9535314 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature